Shares of Novavax, Inc. (NASDAQ:NVAX - Get Free Report) have been given a consensus rating of "Hold" by the seven ratings firms that are presently covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and four have given a buy recommendation to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $17.00.
A number of equities research analysts have recently issued reports on NVAX shares. JPMorgan Chase & Co. dropped their price target on Novavax from $9.00 to $7.00 and set an "underweight" rating for the company in a research report on Friday, May 9th. Citigroup initiated coverage on Novavax in a report on Tuesday, June 17th. They issued a "sell" rating and a $6.00 price objective on the stock. Finally, B. Riley reiterated a "buy" rating on shares of Novavax in a report on Monday, May 19th.
Get Our Latest Analysis on Novavax
Institutional Inflows and Outflows
Large investors have recently added to or reduced their stakes in the company. Bank of New York Mellon Corp raised its stake in shares of Novavax by 0.4% in the fourth quarter. Bank of New York Mellon Corp now owns 436,451 shares of the biopharmaceutical company's stock valued at $3,509,000 after acquiring an additional 1,664 shares in the last quarter. Federated Hermes Inc. raised its stake in Novavax by 4.4% in the fourth quarter. Federated Hermes Inc. now owns 50,506 shares of the biopharmaceutical company's stock valued at $406,000 after buying an additional 2,124 shares in the last quarter. Summit Investment Advisors Inc. raised its stake in Novavax by 16.5% in the fourth quarter. Summit Investment Advisors Inc. now owns 16,126 shares of the biopharmaceutical company's stock valued at $130,000 after buying an additional 2,287 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Novavax by 2.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 104,562 shares of the biopharmaceutical company's stock valued at $678,000 after buying an additional 2,750 shares in the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. raised its stake in Novavax by 9.1% in the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 33,169 shares of the biopharmaceutical company's stock valued at $213,000 after buying an additional 2,780 shares in the last quarter. 53.04% of the stock is currently owned by institutional investors and hedge funds.
Novavax Stock Performance
Shares of Novavax stock traded down $0.21 on Friday, hitting $6.77. The company's stock had a trading volume of 2,603,097 shares, compared to its average volume of 6,253,895. Novavax has a 1 year low of $5.01 and a 1 year high of $17.81. The firm has a fifty day moving average price of $6.80 and a 200-day moving average price of $7.41. The company has a market capitalization of $1.10 billion, a price-to-earnings ratio of 2.55, a price-to-earnings-growth ratio of 0.06 and a beta of 2.69.
Novavax (NASDAQ:NVAX - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported $2.93 EPS for the quarter, topping the consensus estimate of $0.71 by $2.22. The company had revenue of $666.66 million during the quarter, compared to analyst estimates of $204.08 million. Novavax had a negative return on equity of 115.51% and a net margin of 38.14%. Novavax's quarterly revenue was up 610.3% on a year-over-year basis. During the same period in the previous year, the business earned ($1.05) EPS. As a group, analysts forecast that Novavax will post -1.46 EPS for the current year.
About Novavax
(
Get Free ReportNovavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.
See Also

Before you consider Novavax, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novavax wasn't on the list.
While Novavax currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.